Oncogene AS
Score · fiscal year 2025
21of 100
How to read this: the company is ahead of 9 % of companies in the Morning class Micro in the same sector in 2025. What does this mean?
Rank in the Morning class Micro: 1,929 of 2,127 · What are Morning company classes?
Place in the whole sector: 3,843 of 4,183 · Teknisk tjenesteyting og forskning
Profile
Beaver · Builder
Lower profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 6 and solidity 7 out of 100 among companies in the Morning class Micro in the same sector in 2025. Methodology
Against the sector
Oncogene AS is 29 points below the median for companies in the Morning class Micro in the same sector in 2025.
Median score 50 among 2,126 companies.
Against companies in the Morning class Micro in the same sector in 2025: operating margin −177.7% (median 4.9%) and equity ratio 0.5% (median 40.9%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 1 MNOK | 3 MNOK |
| Operating margin | −177.7% | 4.9% |
| Profit margin | −193.4% | 4.8% |
| Return on assets | −35.7% | 10.2% |
| Equity ratio | 0.5% | 40.9% |
| Debt-to-equity | 183.44 | 1.12 |
| Current ratio | 0.24 | 1.66 |
| Revenue growth | 85.4% | 5.2% |
The median and “ahead of” refer to companies in the Morning class Micro in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 21, Oncogene AS does better than 9% of companies in the Morning class Micro in the same sector (2,127 companies) in 2025.
Score over time
Score over time needs at least two fiscal years with a score. It will appear when next year's figures are fetched or history is imported.
Oncogene AS has a score of 21 for 2025, rank 3,843 of 4,183 in the sector.
Strongest: Growth: percentile 91 against peers, revenue growth 85.4% against a median of 5.2%.
Weakest: Liquidity: percentile 2 against peers, current ratio 0.24 against a median of 1.66. Profitability: percentile 6 against peers, operating margin −177.7% against a median of 4.9%.
Worth a closer look
- Consider strengthening liquidity: current liabilities are 4.1 times current assets. Based on: current ratio 0.24 (median 1.66).
- The equity ratio is very low. Could the company absorb a bad year, and does it need more equity? Based on: equity ratio 0.5% (median 40.9%).
- The company made a loss before tax. Are these one-off items or a pattern? Based on: profit margin −193.4% (median 4.8%).
- What lies behind weak profitability, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
The industry or the company: what drove the result?
In 2025 the operating margin of Oncogene AS fell by 208.9 percentage points. Comparable companies fell by a median 0.9 points. So the company did 208.0 points weaker than the industry, for reasons of its own.
| Year | The company | Comparable (median) | Change, company | Change, industry | The company's own |
|---|---|---|---|---|---|
| 2025 | −177.7% | 4.9% | −208.9 percentage points | −0.9 percentage points | −208.0 percentage points |
Comparable companies are those in the same industry and Morning company class. Their change shows what hit the whole industry, the sector drivers below included. The rest is the company's own: contracts, costs, one-off items or operations. The share is approximate, and we claim no cause.
The company and its sector's drivers
Prices, rate and currency that shape the sector's year, year by year beside the operating margin of Oncogene AS. The figures stand side by side; we claim no cause.
Turnover index: architectural and engineering activities (indeks (2021 = 100))
Turnover index: architectural and engineering activities rose 8.1% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Turnover index: architectural and engineering activities, annual average | 99.0 | 108.8 | 127.9 | 146.4 | 158.3 | 155.2 (so far) |
| Change from the year before | +9.8% | +9.9% | +17.5% | +14.5% | +8.1% | −1.9% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: SSB (13863, CC BY 4.0). Source
Turnover index: advertising and market research (indeks (2021 = 100))
Turnover index: advertising and market research rose 3.6% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Turnover index: advertising and market research, annual average | 99.4 | 113.5 | 108.3 | 106.9 | 110.7 | 126.1 (so far) |
| Change from the year before | +35.1% | +14.2% | −4.6% | −1.3% | +3.6% | +13.9% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: SSB (13863, CC BY 4.0). Source
Turnover index: other professional and technical activities (indeks (2021 = 100))
Turnover index: other professional and technical activities rose 6.2% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Turnover index: other professional and technical activities, annual average | 98.3 | 121.6 | 139.4 | 131.0 | 139.1 | 158.0 (so far) |
| Change from the year before | +29.9% | +23.7% | +14.6% | −6.0% | +6.2% | +13.6% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: SSB (13863, CC BY 4.0). Source
Service prices: architects and engineering (indeks (2021 = 100))
Service prices: architects and engineering rose 3.2% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Service prices: architects and engineering, annual average | 100.0 | 103.6 | 107.5 | 111.2 | 114.7 | 119.4 (so far) |
| Change from the year before | +1.2% | +3.5% | +3.8% | +3.4% | +3.2% | +4.2% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: SSB (14335, CC BY 4.0). Source
Oil price (export price of crude oil) (kr per fat)
Oil price (export price of crude oil) fell 17.6% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Oil price (export price of crude oil), annual average | 609 | 979 | 877 | 859 | 708 | 881 (so far) |
| Change from the year before | +61.1% | +60.8% | −10.5% | −2.0% | −17.6% | +24.5% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: SSB (08799, CC BY 4.0). Source
Policy rate (prosent)
Policy rate fell 0.20 percentage points in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Policy rate, annual average | 0.08 | 1.32 | 3.54 | 4.50 | 4.30 | 4.17 (so far) |
| Change from the year before | −0.28 percentage points | +1.24 percentage points | +2.22 percentage points | +0.96 percentage points | −0.20 percentage points | −0.12 percentage points |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: Norges Bank (IR, NLOD 2.0). Source
EUR/NOK (kr)
EUR/NOK rose 0.8% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| EUR/NOK, annual average | 10.16 | 10.10 | 11.42 | 11.62 | 11.72 | 11.04 (so far) |
| Change from the year before | −5.2% | −0.6% | +13.1% | +1.8% | +0.8% | −5.8% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: Norges Bank (EXR, NLOD 2.0). Source
Wage index: architects and engineering (indeks)
Wage index: architects and engineering rose 4.7% in 2025; the operating margin of Oncogene AS fell 208.9 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Wage index: architects and engineering, annual average | 90.5 | 90.9 | 96.0 | 100.9 | 105.6 | 109.2 (so far) |
| Change from the year before | +7.4% | +0.5% | +5.6% | +5.2% | +4.7% | +3.4% |
| The company's operating margin | – | – | – | 31.2% | −177.7% | – |
Source: SSB (12314, CC BY 4.0). Source
We show the drivers and the margin side by side and claim no cause. Sensitivity per company is not computed until we have at least 10 years of accounts per company: with three years such figures are false precision.
What the numbers say
Oncogene AS had an operating margin of −177.7% and an equity ratio of 0.5% in 2025, and ranks 3,843 of 4,183 in Teknisk tjenesteyting og forskning.
From 2024 to 2025: the operating margin fell from 31.2% to −177.7% and went from a profit to a loss before tax.
This text is generated automatically from the 2025 accounts.
Three simple methods
One method gives a figure: 0 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 18.6 | not meaningful |
| EV/EBIT | 15.9 | not meaningful |
| P/B | 3.2 | 0 MNOK |
The listed basis is the value at listed multiples. The estimate is lowered by 51% for an unlisted company: 20% for lack of marketability and 38% for size (a small-company premium of 4% on the cost of equity).
A mechanical estimate from public accounts, not advice. A mechanical estimate from public accounts with listed multiples and fixed adjustments. Not a valuation and not advice to buy or sell. See the calculation
Worth a closer look
- critical
Consider strengthening liquidity: current liabilities are 4.1 times current assets.
Based on: Current ratio 0.24 (median 1.66).
- watch
The equity ratio is very low. Could the company absorb a bad year, and does it need more equity?
Based on: Equity ratio 0.5% (median 40.9%).
- watch
The company made a loss before tax. Are these one-off items or a pattern?
Based on: Profit margin −193.4% (median 4.8%).
- watch
The operating margin is lower than at three in four companies in the sector. Where do costs differ from competitors?
Based on: Operating margin −177.7% (median 4.9%).
- watch
Strong growth with weak liquidity. Is the growth financed, or does it tie up capital the company does not have?
Based on: Revenue growth 85.4% (median 5.2%); Current ratio 0.24 (median 1.66).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 3.2% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
- watch Extreme margin: check the figures
Scenario analysis: the sector's weakest year
We have no accounts for 2021, the sector's weakest year, for this company.
The sector's weakest year was 2021, with a median operating margin of −0.2%. Based on the 8 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 6 | weight 30% |
|---|---|---|
| Solidity | 7 | weight 25% |
| Liquidity | 2 | weight 15% |
| Growth | 91 | weight 15% |
| Consistency | 24 | weight 15% |
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is Oncogene AS?
The operating margin was −177.7% in 2025, against a median of 4.9% among companies in the Morning class Micro in the same sector. Return on assets was −35.7%. The company made a loss before tax.
How solid is Oncogene AS?
The equity ratio was 0.5% in 2025 (median 40.9%). Debt-to-equity was 183.44 (median 1.12).
What is the liquidity of Oncogene AS like?
The current ratio was 0.24 in 2025 (median 1.66). Current assets did not cover current liabilities.
How does Oncogene AS compare in Teknisk tjenesteyting og forskning?
Oncogene AS ranks 3,843 of 4,183 in Teknisk tjenesteyting og forskning for 2025. Among companies in the Morning class Micro it is number 1,929 of 2,127. Revenue changed by 85.4% from the year before.
Group structure · 2025
3 companies in the group according to the shareholder register for 2025. A company counts as a subsidiary when a Norwegian company owns more than half of its shares.
Private persons own 100% of the shares in Modus i AS. Persons are not shown by name.
Modus i AS has not filed group accounts in open data, so the group has no index of its own. Each company has its own accounts.
-
Modus i AS
- Oncogene AS you are here
- Modus X AS
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
Source: the Norwegian Tax Administration's shareholder register 2025 (majority owner with more than 50 % of the shares). Voting agreements and ownership through other countries are not included.
From the Central Coordinating Register
- Org. no.
- 825818642
- Legal form
- AS
- Sector
- Teknisk tjenesteyting og forskning (71.200)
- Morning company class
- Micro
- Employees
- 0–4 (not registered)
- Founded
- 29 September 2020 6 years in operation
- Share capital
- 0.03 MNOK
- Business address
- Gunnar Randers' vei 12, 2007 KJELLER (LILLESTRØM)
- Municipality
- Lillestrøm rank 7 of 11 in KOSTRA group 12
- Audit
- Audit opted out from 21 October 2020
- Latest accounts filed
- 2025
- Website
- oncogene.no
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 1 November 2026. Only names are shown.
Shareholders (2025)
- Number of shareholders
- 6 (one owner holds more than half)
- Largest owner
- 72.0% · top three 87.0%
- Split
- companies 87% · private persons 13% · foreign 0%
- Owned from the same municipality
- 72%
- Owners over 60
- 38% of the shares held by persons (median age 39)
- Group chain
-
Owned by: Modus i AS (72%)
Ultimate owner: private person
- Modus i AS · 72.0%
- Econto AS · 10.0%
- Makri Invest AS · 5.0%
- 3 private persons · 13.0%
The company is new in the shareholder register in 2025.
Source: the Norwegian Tax Administration's shareholder register as of 2025. Figures may be older than today's ownership. Private persons are not shown by name.
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 30 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | – | – | 21 | |
| Rank | – | – | 3,843 | |
| Operating margin | – | 31.2% | −177.7% | |
| Return on assets | −3.2% | 2.7% | −35.7% | |
| Equity ratio | 2.8% | 14.6% | 0.5% | |
| Current ratio | 4.75 | 0.43 | 0.24 | |
| Revenue growth | – | – | 85.4% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | – | 0.6 MNOK | 1.2 MNOK |
| Operating profit | 0.0 MNOK | 0.2 MNOK | −2.1 MNOK |
| Profit before tax | 0.0 MNOK | 0.1 MNOK | −2.3 MNOK |
| Tax expense | 0.0 MNOK | 0.0 MNOK | 0.0 MNOK |
| Net profit | 0.0 MNOK | 0.1 MNOK | −2.3 MNOK |
| Financial expenses | 0.0 MNOK | 0.1 MNOK | 0.2 MNOK |
| Total assets | 1.3 MNOK | 7.5 MNOK | 5.9 MNOK |
| Current assets | 1.2 MNOK | 2.8 MNOK | 1.4 MNOK |
| Equity | 0.0 MNOK | 1.1 MNOK | 0.0 MNOK |
| Retained earnings | 0.0 MNOK | 0.0 MNOK | −2.3 MNOK |
| Total liabilities | 1.3 MNOK | 6.4 MNOK | 5.9 MNOK |
| Current liabilities | 0.2 MNOK | 6.4 MNOK | 5.9 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 30 October 2026, accounts id 7139037.
Further
Similar companies
- Control Union Norge AS index 21, rank 3,845 · compare
- Duoduo AS index 21, rank 3,847 · compare
- Fortress Reklamebyrå AS index 21, rank 3,848 · compare
- Takseringskontoret Otta AS index 21, rank 3,850 · compare
- Lauvdal Foto AS index 21, rank 3,851 · compare